Voya Investment Management LLC Has $8.79 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX

Voya Investment Management LLC boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 25.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 446,399 shares of the biopharmaceutical company’s stock after purchasing an additional 89,498 shares during the quarter. Voya Investment Management LLC owned about 0.36% of Catalyst Pharmaceuticals worth $8,794,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of CPRX. Redhawk Wealth Advisors Inc. increased its stake in Catalyst Pharmaceuticals by 24.7% during the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 67,778 shares of the biopharmaceutical company’s stock worth $1,471,000 after acquiring an additional 13,407 shares during the period. Cresset Asset Management LLC increased its holdings in Catalyst Pharmaceuticals by 588.1% in the 2nd quarter. Cresset Asset Management LLC now owns 87,418 shares of the biopharmaceutical company’s stock valued at $1,897,000 after buying an additional 74,713 shares during the period. Boston Partners raised its position in shares of Catalyst Pharmaceuticals by 0.6% in the 2nd quarter. Boston Partners now owns 1,282,722 shares of the biopharmaceutical company’s stock valued at $27,928,000 after buying an additional 7,397 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in Catalyst Pharmaceuticals by 18.2% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,223,623 shares of the biopharmaceutical company’s stock valued at $26,553,000 after purchasing an additional 188,594 shares in the last quarter. Finally, Swedbank AB bought a new position in shares of Catalyst Pharmaceuticals in the 1st quarter valued at $14,941,000. 79.22% of the stock is owned by institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 26,746 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $23.25, for a total value of $621,844.50. Following the transaction, the director directly owned 2,360 shares of the company’s stock, valued at approximately $54,870. The trade was a 91.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Carmen Jeffrey Del sold 10,983 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $23.33, for a total transaction of $256,233.39. Following the completion of the sale, the insider owned 3,962 shares of the company’s stock, valued at $92,433.46. This represents a 73.49% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $24.23 on Wednesday. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $26.58. The business’s 50 day simple moving average is $22.46 and its 200 day simple moving average is $21.55. The stock has a market capitalization of $2.98 billion, a PE ratio of 14.09, a PEG ratio of 0.86 and a beta of 0.69.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Monday, September 25th. The biopharmaceutical company reported $0.28 EPS for the quarter. Catalyst Pharmaceuticals had a net margin of 37.63% and a return on equity of 39.24%. The company had revenue of $53.11 million for the quarter. As a group, research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.9 earnings per share for the current year.

Catalyst Pharmaceuticals announced that its board has approved a share repurchase program on Wednesday, October 1st that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the biopharmaceutical company to purchase up to 8.3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CPRX. Citigroup lifted their price target on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Wednesday, December 17th. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Finally, Oppenheimer restated an “outperform” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $32.67.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).